Breaking News Instant updates and real-time market news.

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$225.56

-3.18 (-1.39%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55

American Thoracic Society to hold a conference

ATS 2018 will be held in San Diego on May 18-23.

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$225.56

-3.18 (-1.39%)

BIIB

Biogen

$279.68

1.99 (0.72%)

BSX

Boston Scientific

$30.28

-0.37 (-1.21%)

CELG

Celgene

$76.59

1.9 (2.54%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$53.45

0.9 (1.71%)

GSK

GlaxoSmithKline

$40.34

0.29 (0.72%)

HRC

Hill-Rom

$89.79

-0.91 (-1.00%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$32.05

0.19 (0.60%)

OCX

OncoCyte

$2.45

-0.05 (-2.00%)

VVUS

VIVUS

$0.84

0.0406 (5.08%)

NBRV

Nabriva Therapeutics

$4.56

0.015 (0.33%)

MYL

Mylan

$39.22

-0.33 (-0.83%)

MASI

Masimo

$97.94

0.19 (0.19%)

TEVA

Teva

$20.99

-0.1 (-0.47%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$167.12

1.11 (0.67%)

REGN

Regeneron

$294.72

-1.86 (-0.63%)

  • 23

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

BAYRY Bayer
$0.00

(0.00%)

04/10/18
BMOC
04/10/18
DOWNGRADE
Target $128
BMOC
Market Perform
Monsanto downgraded to Market Perform at BMO Capital on Bayer deal prospects
As reported earlier, BMO Capital analyst Joel Jackson downgraded Monsanto (MON) to Market Perform from Outperform while keeping his $128 price target. Jackson cites the rising likelihood of the acquisition by Bayer (BAYRY) after yesterday's reports of approval of the merger by the U.S. Department of Justice. The analyst notes that since the stock price is now so close to Bayer's takeout price, the isn't "sufficient spread" to support a more bullish rating. In the event of a breakdown of the deal, Jackson sees downside support for the stock around $110 per share.
12/29/17
JPMS
12/29/17
NO CHANGE
JPMS
Roche added to Analyst Focus List at JPMorgan
JPMorgan analyst Richard Vosser added Roche (RHHBY) to his firm's Analyst Focus List and keeps an Overweight rating on the shares with a SFR 300 price target. The analyst sees Roche as having the most significant earnings upside potential of any of the European large cap pharma stocks in 2018. He believes the potential of the company's pipeline is being underappreciated at current share levels. His top picks for 2018 are Roche and Bayer (BAYRY).
12/28/17
ARGS
12/28/17
NO CHANGE
Target $470
ARGS
Buy
Regeneron price target lowered to $470 from $540 at Argus
Argus analyst Jasper Hellweg lowered his price target on Regeneron (REGN) to $470 to reflect some of the recent weakness in the stock, but keeps his Buy rating. Hellweg says that while the company's growth has slowed in recent years, it continues to benefit from sales of Eylea, collaboration agreements with Sanofi (SNY) and Bayer (BAYRY) as well as a strong new product pipeline.
04/16/18
ARGS
04/16/18
DOWNGRADE
ARGS
Sell
Monsanto downgraded to Sell from Buy at Argus
Argus analyst Bill Selesky issued a double-notch downgrade on Monsanto (MON) to Sell from Buy after the U.S. Justice Department approved its acquisition by Bayer (BAYRY) last week. The analyst says the deal is expected to be further approved by Canadian and Mexican regulators and completed by the end of Q2. As part of the approval, the analyst points to the companies' pledge to sell additional assets even as Monsanto stock trades just below Bayer's acquisition price of $128 per share.
BDX Becton Dickinson
$225.56

-3.18 (-1.39%)

04/10/18
04/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Ulta Beauty (ULTA) upgraded to Overweight from Neutral at Piper Jaffray with analyst Erinn Murphy citing Piper's 35th semi-annual teens survey in which Ulta Beauty overtook Sephora as the top brand for average-income teens. 2. Nvidia (NVDA) and Seagate (STX) were upgraded to Overweight from Equal Weight at Morgan Stanley. 3. Live Nation (LYV) upgraded to Buy from Neutral at Citi with analyst Jason Bazinet saying the stock has sold off after the New York Times reported that the Department of Justice is investigating the company for antitrust violations. 4. Becton Dickinson (BDX) upgraded to Buy from Neutral at Citi with analyst Amit Hazan saying he sees a "strong setup" for upside to estimates in fiscal 2018, largely driven by the Becton Dickinson side of the business. 5. Illinois Tool Works (ITW) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Joe Ritchie saying the pullback in shares due to auto concerns provides an attractive entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/10/18
SBSH
04/10/18
UPGRADE
Target $251
SBSH
Buy
Becton Dickinson upgraded to Buy from Neutral at Citi
Citi analyst Amit Hazan upgraded Becton Dickinson to Buy and raised his price target for the shares to $251 from $237. The analyst sees a "strong setup" for upside to estimates in fiscal 2018, largely driven by the Becton Dickinson side of the business. Further, he sees drug-coated balloons as an important growth driver for the Bard side of the business.
03/05/18
BMOC
03/05/18
INITIATION
Target $249
BMOC
Market Perform
Becton Dickinson initiated with a Market Perform at BMO Capital
BMO Capital analyst Joanne Wuensch initiated Becton Dickinson with a Market Perform rating and a $249.00 price target.
03/06/18
03/06/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Becton Dickinson (BDX) initiated with a Market Perform at BMO Capital. 2. Cardlytics (CDLX) initiated with a Buy at SunTrust, an Overweight at JPMorgan and KeyBanc, a Neutral at BofA/Merrill, and an Outperform at Wells Fargo. 3. iRhythm (IRTC) initiated with an Outperform at BMO Capital. 4. Genocea (GNCA) initiated with an Overweight at Cantor Fitzgerald. 5. Domino's Pizza (DPZ) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BIIB Biogen
$279.68

1.99 (0.72%)

04/25/18
04/25/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying he is increasingly comfortable with Alphabet's positioning in digital media relative to Facebook (FB), given Alphabet's private relationship with consumers and the high utility and durability of Google's core business. 2. Verizon (VZ) upgraded to Buy from Hold at SunTrust and to Buy from Neutral at UBS. 3. Disney (DIS) upgraded to Market Perform from Underperform at BMO Capital with analyst Daniel Salmon saying the risk-reward on the stock is now more balanced, while its leading portfolio remains a long-term attraction. 4. Biogen (BIIB) upgraded to Outperform from Neutral at Baird with analyst Brian Skorney saying he believes the shares are "too cheap" and its MS business appears more stable than he had been concerned about. 5. PulteGroup (PHM) upgraded to Buy from Neutral at B. Riley FBR and to Buy from Neutral at Buckingham. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/25/18
04/25/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Biogen (BIIB) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Terence Flynn saying pipeline and balance sheet optionality are taking longer to materialize than expected but valuation reflects limited value to Aducanumab or Biogen's Phase 2 neuro pipeline. 2. GrubHub (GRUB) downgraded to Neutral on valuation at Roth Capital with analyst Darren Aftahi citing valuation. 3. Paccar (PCAR) downgraded to Sector Perform from Outperform at RBC Capital and to Neutral from Buy at BofA/Merrill. 4. Caterpillar (CAT) downgraded to Neutral from Outperform at Daiwa. 5. Edwards Lifesciences (EW) downgraded to Market Perform from Outperform at Northland. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/26/18
CANT
04/26/18
NO CHANGE
Target $272
CANT
Neutral
Biogen price target lowered to $272 from $289 at Cantor Fitzgerald
Cantor Fitzgerald analyst William Tanner lowered his price target for Biogen to $17 and reiterates a Neutral rating on the shares following Tuesday's Q1 results. The analyst remains concerned that the company's "out-year growth prospects are too heavily leveraged to the successful development of assets for which significant de-risking may need to occur." Further, the Biogen's multiple sclerosis franchise will continue to face competition, Tanner tells investors in a research note.
05/02/18
SBSH
05/02/18
NO CHANGE
Target $290
SBSH
Neutral
Biogen price target lowered to $290 from $360 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen to $290 saying Tecfidera "is an unanswered question and a big risk to the stock." The analyst is unsure what the generic Gilenya impact will be on Tecfidera. Biogen shares may not be at a bad entry point for long-term investors, but "we don't think this is where people need to be over the next year," Karnauskas tells investors in research note. She believes the key issue for the shares is the Alzheimer's program and expects data late in 2019 or early 2020. The analyst keeps a Neutral rating on Biogen.
BSX Boston Scientific
$30.28

-0.37 (-1.21%)

05/14/18
STFL
05/14/18
NO CHANGE
Target $33
STFL
Buy
Boston Scientific mesh issues likely overstated by 60 Minutes, says Stifel
Stifel analyst Rick Wise commented on the "60 Minutes" story regarding Boston Scientific transvaginal mesh products and associated lawsuits, calling the report "unsettling...but likely overstated." He notes that the company has reached or is near settlement on 47,500 of the known 49,500 mesh legal claims, has a $1.5B legal reserve for the matter and has said it expects the majority of the remaining mesh claims to be resolved in 2018. Wise keeps a Buy rating and $33 price target on Boston Scientific shares.
03/19/18
MSCO
03/19/18
NO CHANGE
Target $33
MSCO
Overweight
Boston Scientific price target raised to $33 from $30 at Morgan Stanley
Morgan Stanley analyst David Lewis raised his price target on Boston Scientific to $33 and kept his Overweight rating, citing the company's outperforming growth profile and balance sheet flexibility. Lewis says the company can sustain a 6%-7% organic expansion with its pipeline and a shift to higher growth end markets, which are ineffectively reflected in valuation. The analyst adds that while the selloff was driven by concerns around Lotus Edge, the product is "more of a call option" based on the company's core performance.
03/22/18
ADAM
03/22/18
NO CHANGE
Target $35
ADAM
Buy
Canaccord remains a buyer of Boston Scientific following NxThera deal
Canaccord analyst Jason Mills said he would remain a buyer of Boston Scientific following the company's announcement that it will buy NxThera, which which has developed treatments for endo-urological conditions like benign prostatic hyperplasia, or BPH. In a research note to investors, Mills said Boston Scientific raises the long-term growth potential of its Urology and Pelvic Health portfolio, ultimately being in position to sell both surgical and MIS BPH therapeutic modalities.Mills, who has a Buy rating and $35 price target on Boston Scientific shares, expects the company to become "increasingly" active in M&A, noting that he likes the company's strategic vision and potential, and is "bullish" about the growth prospects of its core franchises.
03/26/18
WELS
03/26/18
NO CHANGE
WELS
IPR decision a 'nice' win for Edwards Lifesciences, says Wells Fargo
Wells Fargo analyst Lawrence Biegelsen notes USPTO has determined that all claims of the '608 patent that have been asserted against Edwards Lifesciences (EW) are invalid, which the analyst sees as an important victory for the company because the '608 patent is one of Boston Scientific's (BSX) key transcatheter valve patents. While Boston Scientific will appeal the USPTO's decision on the '608 patent, Biegelsen's patent consultant believes the company's chances of overturning the decision are very low.
CELG Celgene
$76.59

1.9 (2.54%)

05/07/18
LEER
05/07/18
NO CHANGE
Target $115
LEER
Outperform
Celgene price target lowered to $115 from $123 at Leerink
Leerink analyst Geoffrey Porges raised his price target for Celgene to $115 from $123 after the company announced Q4 results with a modest beat in revenues and pro forma EPS compared to consensus and significant delays in timing for two important development programs connected to ozanimod. Nonetheless, the analyst reiterates an Outperform rating, given the value of the company's existing products, and tangible late stage pipeline.
05/04/18
PIPR
05/04/18
NO CHANGE
Target $95
PIPR
Neutral
Piper remains on sidelines after Celgene's 'surprisingly strong' Q1
Piper Jaffray analyst Christopher Raymond says that while he's encouraged by Celgene's "surprisingly strong" Q1 beat and "relatively timely" resubmission of ozanimod's multiple sclerosis new drug application, he remains concerned over the company's ability to diversify away from Revlimid. The analyst prefers to stay on the sidelines and keeps a Neutral rating on Celgene shares with a $95 price target.
05/21/18
RBCM
05/21/18
NO CHANGE
Target $118
RBCM
Outperform
Celgene weakness on executive change report 'unfounded,' says RBC Capital
RBC Capital analyst Brian Abrahams said he believes weakness related to a news article discussing the departure of George Golumbeski from Celgene is "unfounded," as his understanding based on talks with the company and LinkedIn info is that Rob Hershberg has already been running business development at the company for over a year and that Golumbeski had transitioned to more of a strategic role prior to his exit. Given the transition was in the works for some time, he does not see any relation between reports about this emerging today and proximity to upcoming readouts, said Abrahams, who keeps an Outperform rating on Celgene shares.
05/07/18
RBCM
05/07/18
DOWNGRADE
Target $118
RBCM
Outperform
Celgene downgraded to Outperform from Top Pick at RBC Capital
RBC Capital analyst Brian Abrahams downgraded Celgene to Outperform from Top Pick and lowered his price target for the shares to $118 from $120. The analyst continues to view the valuation as compelling, but he thinks other names offer more upside without more pipeline and Revlimid intellectual property visibility. Abrahams remains a buyer of Celgene shares.
DNA Bought by RHHBY
$0.00

(0.00%)

10/13/17
KEYB
10/13/17
NO CHANGE
Target $106
KEYB
Overweight
Auto suppliers supported by stronger Euro and rising EU output, says KeyBanc
KeyBanc analyst Brett Hoselton raised his profit targets on several auto suppliers, maintaining a positive view on the group overall heading into Q3 earnings. Hoselton says the outlook for the quarter is intact, as lower than expected production of light vehicles was in part offset by stronger EU output. He also cites FX tailwinds, with the Euro have appreciated about 7% sequentially and further supporting revenue in Q3 and possibly FY18. Hoselton raised his profit targets on Delphi Automotive (DLPH) to $106 from $100, Magna International (MGA) to $59 from $55, Lear Corp (LEA) to $184 from $180, and BorgWarner (BWA) to $56 from $50, maintaining an Overweight rating on all these stocks. The analyst is especially bullish on Dana Inc (DNA) given the recent upward revisions to North America Class 8 production, but says his Sector Weight rating reflects the stock prices.
FGEN FibroGen
$53.45

0.9 (1.71%)

05/15/18
MZHO
05/15/18
UPGRADE
Target $61
MZHO
Buy
FibroGen upgraded to Buy from Neutral at Mizuho
Mizuho analyst Difei Yang upgraded FibroGen to Buy with an unchanged price target of $61. With a "solid" cash position, the company continues to make progress on its research and development pipeline, Yang tells investors in a research note. The analyst expects top-line Phase 3 data from Roxadustat in chronic kidney disease in Q4 and a potential regulatory approval in China is expected by year-end 2018. Yang believes believe FibroGen is likely to gain the first approval in new generation anemia drugs.
02/28/18
LEER
02/28/18
NO CHANGE
Target $88
LEER
Outperform
FibroGen price target raised to $88 from $80 at Leerink
Leerink analyst Geoffrey Porges raised his price target for FibroGen to $88 from $80 after the company n reported Q4 financial and operational results, and provided updated later timing for the U.S. roxadustat phase III trials and approval in chronic kidney disease. The analyst reiterates an Outperform rating on the shares.
11/15/17
HCWC
11/15/17
NO CHANGE
Target $24
HCWC
Buy
Akebia recent selloff not based on fundamentals, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce notes that since the close on November 8, shares of FibroGen (FGEN) are down 17% while Akebia Therapeutics (AKBA) is down 21.3%. He attributes some of the weakness to FibroGen's Q3 earnings call, in which concerns arose that cardiovascular events in the large Phase 3 roxadustat cardiovascular outcomes trials are accruing too slowly. The analyst believes this has no fundamental bearing on Akebia or vadadustat, however. He keeps a Buy rating on the shares with a $24 price target.
12/18/17
PIPR
12/18/17
INITIATION
Target $26
PIPR
Overweight
Akebia initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond initiated Akebia (AKBA) with an Overweight rating and a price target of $26. The analyst cites the company's "combination of sound biology, clean safety, meaningful unmet medical need and an attractive relative valuation". While the near term prospects for Akebia revolve around first-to- market player Fibrogen (FGEN) in the HIF space, the analyst contends, Akebia can generate its own share of anemia market once its lead compound vadadustat is approved.
GSK GlaxoSmithKline
$40.34

0.29 (0.72%)

05/16/18
SPHN
05/16/18
INITIATION
Target $16
SPHN
Overweight
Codexis initiated with an Overweight at Stephens
Stephens analyst Drew Jones started Codexis (CDXS) with an Overweight rating and $16 price target, stating that the company's CodeEvolver platform technology has been sought by pharma partners Merck (MRK), GlaxoSmithKline (GSK) and Nestle (NSRGY) and he expects continued deeper adoption from other major industry players.
04/04/18
04/04/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Buy from Hold at HSBC. 2. GlaxoSmithKline (GSK) upgraded to Outperform from Neutral at Exane BNP Paribas. 3. BHP Billiton (BHP) upgraded to Sector Perform from Underperform at RBC Capital and to Buy from Neutral at Citi. 4. Boston Beer (SAM) upgraded to Market Perform from Underperform at Cowen with analyst Vivien Azer citing strong Nielsen data in the non-beer category. 5. EnLink Midstream Partners (ENLK) upgraded to Overweight from Neutral at JPMorgan with analyst Jeremy Tonet saying he reduced his distribution growth expectations given the elevated cost of equity, but views the current 11.5% yield as sustainable. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/04/18
EXAN
04/04/18
UPGRADE
EXAN
Outperform
GlaxoSmithKline upgraded to Outperform from Neutral at Exane BNP Paribas
Exane BNP Paribas analyst Kerry Holford upgraded GlaxoSmithKline to Outperform with an increased price target of GBP 16.30.
04/25/18
WELS
04/25/18
NO CHANGE
WELS
Market Perform
Glaxo comments on Advair have negative read through for Mylan, says Wells Fargo
Noting that GlaxoSmithKline (GSK) said it now expects branded Advair sales to decline 30% this year, even excluding the impact of a generic, Wells Fargo analyst David Maris said the news has a negative read through for Mylan (MYL) given that its generic Advair is one of the company's highest profile pipeline items. While Advair will be a good generic opportunity, it represents "a fraction of what some might have previously believed," said Maris, who has a Market Perform rating on Mylan shares.
HRC Hill-Rom
$89.79

-0.91 (-1.00%)

01/03/18
RAJA
01/03/18
UPGRADE
Target $94
RAJA
Outperform
Hill-Rom upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Lawrence Keusch upgraded Hill-Rom to Outperform from Market Perform and established a $94 price target. He expects accelerating revenue growth to 4%+ in FY18 up from 3% core growth in FY17, continued margin expansion opportunities, and potential upside from capital deployment. The analyst is confident the company can deliver revenue growth acceleration through new products and expects margin expansion more consistent with management's guidance.
04/04/18
GSCO
04/04/18
INITIATION
Target $85
GSCO
Neutral
Hill-Rom initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Issac Ro started Hill-Rom with a Neutral rating and $85 price target.
01/16/18
NEED
01/16/18
NO CHANGE
Target $105
NEED
Buy
Hill-Rom price target raised to $105 from $90 at Needham
Needham analyst Mike Matson raised his price target on Hill-Rom to $105 after the company's above-consensus pre-announced Q1 results due to the positive impact of U.S. tax reform. Matson also cites the management's view of revenue upside across the company's businesses as well as the stock price trading at a 22% discount relative to small / mid-cap value peers' median FY18 PE, keeping his Buy rating on Hill-Rom.
02/13/18
NEED
02/13/18
NO CHANGE
NEED
Needham a buyer of Medical Technologies product makers on Amazon headlines
After The Wall Street Journal report claiming that Amazon (AMZN) is attempting to become a major hospital supplier, Needham analyst Mike Matson said that he believes the e-commerce giant has typically disrupted middlemen much more than manufacturers. The analyst, who thinks Amazon's model may work for "lower tech" products but is unlikely to work with "higher tech" products, would be a buyer of Medical Technologies product maker stocks if they are down on weakness related to the headline risk represented by Amazon. However, Matson notes that he believe that Cantel Medical (CMD), CONMED (CNMD), Medtronic (MDT), Stryker (SYK) and Teleflex (TFX) generate a portion of their sales from "lower tech" products. Other stocks in MedTech manufacturing include AtriCure (ATRI), Cardiovascular Systems (CSII), Hill-Rom (HRC), K2M Group (KTWO), Mazor Robotics (MZOR), Zimmer Biomet (ZBH), Boston Scientific (BSX), Globus Medical (GMED), NuVasive (NUVA) and Wright Medical (WMGI).
INNV Innovus Pharmaceuticals
$0.00

(0.00%)

RETA Reata Pharmaceuticals
$32.05

0.19 (0.60%)

08/30/17
JEFF
08/30/17
INITIATION
Target $44
JEFF
Buy
Reata Pharmaceuticals initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started Reata Pharmaceuticals with a Buy rating and $44 price target. The company is positioned to "pursue several valuable orphan indication" markets with potential for broader use, Raycroft tells investors in a research note.
09/13/17
LEER
09/13/17
INITIATION
Target $43
LEER
Outperform
Reata Pharmaceuticals initiated with an Outperform at Leerink
Leerink analyst Joseph Schwartz started Reata Pharmaceuticals with an Outperform rating and $43 price target as he believes the company has a "strong development strategy" for its novel platform as evidenced by recent positive data in two orphan indications, and expects upcoming data in others to expand investor appreciation.
11/06/17
SBSH
11/06/17
NO CHANGE
Target $78
SBSH
Buy
Citi says time to believe in Reata's Alport syndrome data
Citi analyst Yigal Nochomovitz says it is time to believe Reata Pharmaceuticals' Alport syndrome data "are real" after the company presented positive 12-week data from the Phase 2 Cardinal trial testing bardoxolone. The shares sold off 4% Friday despite a "consistent and increasing benefit" in eGFR, a measure of kidney function, over time in a genetically-driven disease where decline in kidney function is the norm, Nochomovitz writes in a research note. Investors were hesitant to believe the data in July with only 8 patients reaching 12 weeks, but now all 30 have completed the trial and the results "are only better," the analyst contends. He keeps a Buy rating on Reata with a $78 price target. The stock closed Friday down $1.09 to $28.92.
07/25/17
SBSH
07/25/17
NO CHANGE
Target $87
SBSH
Buy
Reata Pharmaceuticals price target raised to $87 from $39 at Citi
Citi analyst Yigal Nochomovitz more than doubled his price target for shares of Reata Pharmaceuticals to $87 from $39. The clinical-stage biopharmaceutical company closed yesterday up $4.37, or 14%, to $35.47. The company yesterday reported "unexpected and highly impressive" results from a Phase 2 trial testing Bardoxolone in Alport Syndrome, Nochomovitz tells investors in a research note. The data suggest "very meaningful disease reversal," the analyst argues. He believes the planned Phase 3, with data expected in 2019, should work with at least a 60% probability. Nochomovitz keeps a Buy rating on Reata shares.
OCX OncoCyte
$2.45

-0.05 (-2.00%)

03/21/18
JANY
03/21/18
DOWNGRADE
JANY
Neutral
OncoCyte downgraded to Neutral from Buy at Janney Capital
03/21/18
03/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Match Group (MTCH) downgraded to Neutral from Buy at Guggenheim. 2. Sarepta (SRPT), Global Blood Therapeutics (GBT), and Loxo Oncology (LOXO) were downgraded to Equal Weight from Overweight at Morgan Stanley. 3. Instructure (INST) downgraded to Buy from Strong Buy at Needham with analyst Scott Berg citing valuation, with the stock price having run up 133% since the start of 2017. 4. OncoCyte (OCX) downgraded to Neutral from Buy at Janney Capital. 5. Cboe Global Markets (CBOE) downgraded to Underweight from Neutral at JPMorgan with analyst Kenneth Worthington saying despite the stock market recovery, Cboe's risk/reward is skewed to the downside as pressure on the VIX futures is likely to continue. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/23/17
BNCH
05/23/17
NO CHANGE
Target $12
BNCH
Speculative Buy
OncoCyte price target raised to $12 after 'strong' lung test data at Benchmark
Benchmark analyst Raymond Myers said OncoCyte reported "strong" validation study results for its lung cancer diagnostic test, noting that the 73% specificity reported was "meaningfully better" than the 50% specificity threshold he estimates is necessary to support commercial success for the test. The study reduces OncoCyte's risk profile and supports increasing his price target on the stock to $12 from $10, he tells investors. Myers keeps a Speculative Buy rating on OncoCyte shares.
VVUS VIVUS
$0.84

0.0406 (5.08%)

NBRV Nabriva Therapeutics
$4.56

0.015 (0.33%)

05/21/18
HCWC
05/21/18
NO CHANGE
HCWC
Nabriva LEAP 2 data signals likely 2019 approval, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce said the positive pivotal Phase 3 LEAP 2 lefamulin data that Nabriva Therapeutics announced Monday morning means that lefamulin could be approved in the U.S. as soon as mid-2019, assuming the company's request for priority review is granted. The analyst affirmed his Buy rating on Nabriva shares.
01/18/18
MSCO
01/18/18
INITIATION
Target $10
MSCO
Overweight
Nabriva Therapeutics initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Andrew Berens started Nabriva Therapeutics yesterday with an Overweight rating and $10 price target.
11/16/17
HCWC
11/16/17
NO CHANGE
Target $20
HCWC
Buy
Nabriva shares still look 'significantly undervalued,' says H.C. Wainwright
H.C. Wainwright analyst Ed Arce says that with Leap 2 trial enrollment completion in Q4 and the top-line results in the spring of 2018, shares of Nabriva Therapeutics continue to look "significantly undervalued." The analyst continues to expect favorable results from the pivotal study in moderate to severe community-acquired bacterial pneumonia patients. He affirms a Buy rating on Nabriva with a $20 price target.
03/21/18
BOFA
03/21/18
INITIATION
Target $10
BOFA
Buy
Nabriva Therapeutics initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Jason Gerberry initiated Nabriva Therapeutics with a Buy and $10 saying it has a "unique antibiotic class" and an attractive valuation. Gerberry said the key catalyst is lefamulin in Phase 3 development for the treatment of community-acquired bacterial pneumonia, which he believes has a competitive profile and assigns a 70% probability of success.
MYL Mylan
$39.22

-0.33 (-0.83%)

04/23/18
WELS
04/23/18
NO CHANGE
WELS
Market Perform
Mylan layoffs will led to questions, says Wells Fargo
Wells Fargo analyst David Maris acknowledges press reports that Mylan is laying off approximately 500 employees, or approximately 15% of its employees in Morgantown, Virginia. Investors will have questions when Mylan reports Q1 results about the layoffs and what Mylan means about the need to make the Morgantown plant less complex, Maris tells investors in a research note. He keeps a Market Perform on Mylan shares.
05/15/18
MZHO
05/15/18
UPGRADE
Target $27
MZHO
Buy
Mizuho compares Valeant portfolio to Mylan in upgrade to Buy
Mizuho analyst Irina Koffler upgraded Valeant Pharmaceuticals (VRX) to Buy from Neutral and raised her price target for the shares to $27 from $15. The stock closed yesterday down 4c to $20.81. Adjusting individual product growth estimates has made the analyst more constructive on Valeant's turnaround story. The company's portfolio now looks Mylan-like (MYL) in that 70% of revenue consists of stable products that are either consumer-focused, or older drugs that are already generic, Koffler tells investors in a research note. Further, the analyst sees growth potential from Valeant's pipeline, which she notes contains multiple catalysts in 2018-2020 and is not in her estimates. She thinks that in order for the stock to work over the next year, Valeant just needs to execute on its quarters and push through new product launches.
05/18/18
BERN
05/18/18
NO CHANGE
Target $54
BERN
Outperform
Biocon 483 letter won't delay approval of Mylan's Neulasta, says Bernstein
Bernstein analyst Aaron Gal said that the 483 letter for Biocon's Bangalore facility contains seven observations, all related to cleaning procedures, and does not contain any argument of systemic or recurring problem, suggestions of any of the procedure deviations creating patient risk or problems requiring changes in the facility structure or equipment. In a research note to investors, Gal said the 483 is viewed as being on the "lighter side," and can be "reasonably" addressed through change in procedure, and does not believe it will delay the tentative approval of Biocon/Mylan's Neulasta. The analyst has an Outperform rating and $54 price target on Mylan.
MASI Masimo
$97.94

0.19 (0.19%)

03/09/18
03/09/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Corcept Therapeutics (CORT) initiated with a Buy at B. Riley FBR. 2. Masimo (MASI) initiated with an Overweight at Barclays. 3. Ovid Therapeutics (OVID) initiated with an Overweight at Piper Jaffray. 4. Endocyte (ECYT) initiated with an Outperform at Wells Fargo. 5. Cloudera (CLDR) initiated with a Neutral at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/09/18
LEHM
03/09/18
INITIATION
Target $97
LEHM
Overweight
Masimo initiated with an Overweight at Barclays
Barclays analyst Matthew Taylor started Masimo with an Overweight rating and $97 price target. The company has am "impressive history" of innovation, core competencies in engineering/signal processing, and a start-up culture that "make it stand out," the analyst contends. He believes Masimo is gaining share in its core pulse-oximetry market.
08/14/17
08/14/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. International Paper (IP) upgraded to Buy from Neutral at DA Davidson with analyst Steven Chercover citing the 18% upside to his price target of $62 as well as the 3.5% dividend yield. 2. Masimo (MASI) upgraded to Buy from Neutral with analyst Sean Lavin saying he is more bullish on the Philips (PHG) agreement leading to increased revenue and margins, and the recent share pullback has provided a buying opportunity. Further, the analyst thinks Johnson & Johnson (JNJ) could be an acquirer of Masimo as it sells its products into the OR and ICU markets and would "massively" expand operating margins, and notes Philips may see the value of Masimo's products and make a bid. 3. NetApp (NTAP) upgraded to Buy from Hold at Maxim with analyst Nehal Chokshi saying channel checks indicate the company's hybrid cloud capabilities have gained traction. 4. Orbital ATK (OA) upgraded to Buy from Hold at Argus with analyst David Coleman citing valuation and his belief that its cash flow can increase. 5. Werner (WERN) upgraded to Overweight from Equal Weight at Stephens with analyst Brad Delco saying it is an attractive way to play an inflection in TL fundamentals. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/02/18
PIPR
05/02/18
NO CHANGE
Target $94
PIPR
Neutral
Masimo price target raised to $94 from $91 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target on Masimo to $94 after its Q1 earnings beat and raised guidance for FY18, saying the company's driver shipments in the quarter reflects the ongoing strength of its Signal Extraction Technology - SET - business. The analyst further cites the management's commentary that growth was evident in both the U.S. and the overseas markets while also pointing to the company's expected stock buybacks being favored over large M&A deals. Quirk keeps his Neutral rating on Masimo, stating that despite the better than expected results, the company's risk-reward is balanced at current levels.
TEVA Teva
$20.99

-0.1 (-0.47%)

05/18/18
CANT
05/18/18
NO CHANGE
Target $18
CANT
Neutral
Amgen approval in migraine positive for Teva, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen thinks FDA approval of Amgen's (AMGN) Aimovig is positive for Teva (TEVA) as well as other new potential migraine treatments coming to the market because it underscores the large unmet need. She notes, however, that Teva does not expect approval until later this year given its manufacturing issues. The analyst keeps a Neutral rating on Teva with an $18 price target.
05/18/18
WELS
05/18/18
NO CHANGE
WELS
Amgen migraine drug price may be below expectations, says Wells Fargo
The FDA, as expected, approved Amgen (AMGN) and Novartis' (NVS) first-in-class anti-CGRP treatment Aimovig for the prevention of migraine, Wells Fargo analyst David Maris tells investors in a research note. The only part of the news which may be somewhat unexpected could be the pricing, which came in at $575 per month or $6,900 annually, the analyst adds. He thinks some investors may have been expecting the price in the $12,000 range. Maris thinks there may be a potential negative read-through on the pricing for Teva (TEVA) and to a lesser extent, Allergan (AGN).
05/07/18
FBCO
05/07/18
NO CHANGE
Target $23
FBCO
Outperform
Teva turnaround story appears generally on track, says Credit Suisse
Credit Suisse analyst Vamil Divan believes Teva's Q1 earnings were "solid" and sees his bullish thesis on the company as being on track. The analyst notes that the company's restructuring program is proceeding in line with its prior guidance and his expectations, if even a bit ahead of schedule. Divan reiterates an Outperform rating and $23 price target on the shares.
05/03/18
WELS
05/03/18
NO CHANGE
Target $16.5
WELS
Underperform
Teva Q1 'just what investors wanted,' says Wells Fargo
Wells Fargo analyst David Maris believes this quarter is exactly the quarter investors wanted out of Teva, namely progress on the cost cutting and raised guidance on the back of a business that is still facing a significant decline given a tough U.S. generics environment and generic Copaxone pressures. The analyst reiterates an Underperform rating and $16.50 price target on the shares.
STEM Ticker changed to MBOT
$0.00

(0.00%)

JAZZ Jazz Pharmaceuticals
$167.12

1.11 (0.67%)

04/12/18
PIPR
04/12/18
NO CHANGE
Target $201
PIPR
Overweight
Jazz remains high conviction specialty pharma idea at Piper Jaffray
After surveying 25 physicians who treat a significant number of obstructive sleep apnea and narcolepsy patients, Piper Jaffray analyst David Amsellem believes peak U.S. sales potential for Jazz Pharmaceuticals' solriamfetol of at least $400M in the OSA/narcolepsy setting is realistic, "particularly given the sizable portion of patients who do not respond adequately to existing options." Solriamfetol helps position Jazz for annual double-digit EBITDA growth over the next several years, Amsellem tells investors in a research note. He calls Jazz one of his highest conviction specialty pharma ideas. The analyst reiterates an Overweight rating on the shares with a $201 price target.
05/01/18
RILY
05/01/18
NO CHANGE
Target $206
RILY
Buy
Jazz Pharmaceuticals named Alpha Generator Pick at B. Riley FBR
B. Riley FBR analyst David Buck named Jazz Pharmaceuticals his Alpha Generator Pick and keeps a Buy rating on the shares with a $206 price target. The analyst views the company's in-line product growth as attractive.
05/15/18
WELS
05/15/18
NO CHANGE
WELS
Jazz Pharmaceuticals price target raised to $182 from $176 at Wells Fargo
Wells Fargo analyst David Maris maintained an Outperform rating on Jazz Pharmaceuticals and raised his price target to $182 from $176 on Jazz shares. The analyst also raised his 2018 EPS estimate to $13.00 from $12.91 after Jazz's beat and raise quarter, and raised his outer year Xyrem growth forecasts from 8% to 10% in 2019, from 6% to 8% in 2020 and from 4% to 5% in 2021, based on Xyrem's return to stronger growth in Q1. Maris concluded that he liked " the conservative balance sheet and potential for strategic deals, the current sales trends, and the focus on pipeline progress."
05/01/18
MZHO
05/01/18
NO CHANGE
Target $91
MZHO
Buy
Spark Therapeutics price target raised to $91 from $79 at Mizuho
Mizuho analyst Difei Yang raised her price target for Spark Therapeutics (ONCE) to $91 citing the priority review voucher sale to Jazz Pharmaceuticals (JAZZ) as well as "probability adjusted M&A premium." Spark is one of the highest-quality gene therapy companies, so it is reasonable to apply a conservative takeover premium to the stock's valuation, Yang tells investors in a research note. The analyst reiterates a Buy rating on the shares.
REGN Regeneron
$294.72

-1.86 (-0.63%)

05/07/18
RBCM
05/07/18
NO CHANGE
Target $342
RBCM
Sector Perform
Regeneron price target lowered to $342 from $430 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Regeneron to $342 and kept his Sector Perform rating. The analyst says that while Eylea sales exceeded his expectations in Q1, he sees continued pressure for the stock from increasing competition for both Eylea and Dupixent as well as a reimbursement pushback for the latter, reducing his sales expectations on both of these programs.
05/08/18
PIPR
05/08/18
NO CHANGE
Target $450
PIPR
Overweight
Piper survey shows 'significant progress' for Regeneron's Dupixent
Piper Jaffray analyst Christopher Raymond says his new survey work indicates "significant progress" for Regeneron Pharmaceuticals' Dupixent both in terms of the drug's quantitative use trends and dermatologists' qualitative views of the drug's commercialization. As such, the analyst believes Dupixent is poised for a "sharp rebound" beginning this quarter, with "significant follow-through" for the remainder of 2018. He maintains above consensus estimates on Dupixent and would be buyers of Regeneron shares on the weakness. Despite the "dismal" year-to-date performance, the stock can "rebound nicely especially on any sign of unexpected commercial traction," Raymond tells investors in a research note. He keeps an Overweight rating on Regeneron with a $450 price target.
05/04/18
LEER
05/04/18
NO CHANGE
Target $435
LEER
Outperform
Regeneron price target lowered to $435 from $502 at Leerink
Leerink analyst Geoffrey Porges noted that Regeneron reported mixed Q1 results, stating that Eylea "reassuringly" beat consensus but Dupixent, Kevzara and Praluent fell short of consensus estimates. The big question for Q2 will be the magnitude of recovery in U.S. Dupixent sales, said Porges, who believes better performance for Dupixent, sustained growth in Eylea, growth in Praluent and initial sales of cemiplimab are all essential for Regeneron's stock to recover in the second half of 2018. He maintains an Outperform rating on the stock but lowered his Regeneron price target to $435 from $502.
05/04/18
COWN
05/04/18
NO CHANGE
Target $350
COWN
Outperform
Regeneron price target lowered to $350 from $400 at Cowen
Cowen analyst Phil Nadeau lowered his price target on Regeneron to $350 from $400 to reflect increasing competition and its effect on free cash flow. Nadeau maintained his Outperform rating on Regeneron shares, noting that the company's conference call highlighted the potential growth opportunities for Eylea as well as it allergy and IO franchises.

TODAY'S FREE FLY STORIES

MMSI

Merit Medical

$49.50

-0.6 (-1.20%)

12:55
06/18/18
06/18
12:55
06/18/18
12:55
Recommendations
Merit Medical analyst commentary  »

Merit Medical could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

  • 12

    Jul

12:55
06/18/18
06/18
12:55
06/18/18
12:55
General news
Treasury Action: yields rebounded from lows with stocks »

Treasury Action: yields…

NEWT

Newtek Business Services

$19.40

0.3 (1.57%)

12:54
06/18/18
06/18
12:54
06/18/18
12:54
Hot Stocks
Newtek Business Services raises 2018 annual dividend forecast to $1.72 per share »

Newtek Business Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

AAL

American Airlines

$42.36

-0.4 (-0.94%)

, LUV

Southwest

$52.02

-0.145 (-0.28%)

12:51
06/18/18
06/18
12:51
06/18/18
12:51
Periodicals
JetBlue founder plans to launch new airline, Airline Weekly reports »

JetBlue (JBLU) founder…

AAL

American Airlines

$42.36

-0.4 (-0.94%)

LUV

Southwest

$52.02

-0.145 (-0.28%)

UAL

United Continental

$74.18

0.29 (0.39%)

JBLU

JetBlue

$19.14

-0.05 (-0.26%)

DAL

Delta Air Lines

$54.77

-0.4 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 26

    Jul

XHB

SPDR Homebuilders

$40.50

-0.36 (-0.88%)

12:50
06/18/18
06/18
12:50
06/18/18
12:50
Options
Put buyers in SPDR Homebuilders ETF ahead of data »

Put buyers in SPDR…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LUNA

Luna Innovations

$3.01

-0.04 (-1.31%)

12:46
06/18/18
06/18
12:46
06/18/18
12:46
Hot Stocks
Breaking Hot Stocks news story on Luna Innovations »

Leviticus Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$16.65

0.69 (4.32%)

12:45
06/18/18
06/18
12:45
06/18/18
12:45
Options
Range Resources call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

12:45
06/18/18
06/18
12:45
06/18/18
12:45
General news
Breaking General news story  »

Atlanta Federal Reserve…

SQ

Square

$65.15

0.595 (0.92%)

, TWTR

Twitter

$45.77

-0.03 (-0.07%)

12:43
06/18/18
06/18
12:43
06/18/18
12:43
Hot Stocks
Square moves higher after being granted cryptocurrency license in New York »

Shares of Square (SQ)…

SQ

Square

$65.15

0.595 (0.92%)

TWTR

Twitter

$45.77

-0.03 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

SJM

J.M. Smucker

$103.74

-1.95 (-1.85%)

12:35
06/18/18
06/18
12:35
06/18/18
12:35
Options
J.M. Smucker put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

AAPL

Apple

$188.89

0.02 (0.01%)

12:34
06/18/18
06/18
12:34
06/18/18
12:34
Periodicals
Apple Pay to launch in Poland on Tuesday, Cashless reports »

Apple Pay (AAPL) will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

GM

General Motors

$43.89

-0.02 (-0.05%)

12:29
06/18/18
06/18
12:29
06/18/18
12:29
Periodicals
GM to invest $175M to retool Michigan plant for Cadillac sedans, Reuters reports »

General Motors is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

AWK

American Water

$81.42

0.36 (0.44%)

12:26
06/18/18
06/18
12:26
06/18/18
12:26
Hot Stocks
American Water investing over $14M to replace, install 48k feet of water main »

linois American…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
06/18/18
06/18
12:25
06/18/18
12:25
Conference/Events
Federal Reserve Bank of Atlanta president speaks at a meeting »

Atlanta Federal Reserve…

BDX

Becton Dickinson

$229.87

-2.3 (-0.99%)

12:25
06/18/18
06/18
12:25
06/18/18
12:25
Conference/Events
Becton Dickinson has a conference call hosted by William Blair »

William Blair hosts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

AWK

American Water

$81.37

0.31 (0.38%)

12:24
06/18/18
06/18
12:24
06/18/18
12:24
Hot Stocks
American Water to invest $2.3M to upgrade 7,100 feet of water main in Pekin »

Illinois American Water…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$14.70

2.675 (22.25%)

12:20
06/18/18
06/18
12:20
06/18/18
12:20
Options
Active trading in Rent A Center as shares rally »

Active trading in Rent A…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$14.71

2.685 (22.33%)

, WPC

W.P. Carey

$65.68

-1.37 (-2.04%)

12:18
06/18/18
06/18
12:18
06/18/18
12:18
General news
On The Fly: Top stock stories at midday »

Stocks opened sharply…

RCII

Rent-A-Center

$14.71

2.685 (22.33%)

WPC

W.P. Carey

$65.68

-1.37 (-2.04%)

JD

JD.com

$43.98

0.35 (0.80%)

GOOG

Alphabet

$1,164.30

12.35 (1.07%)

GOOGL

Alphabet Class A

$1,174.85

15.82 (1.36%)

ARWR

Arrowhead

$13.90

2.83 (25.56%)

CBPO

China Biologic

$99.99

18.09 (22.09%)

CBIO

Catalyst Biosciences

$10.81

-14.52 (-57.32%)

ZIOP

Ziopharm

$3.55

-0.76 (-17.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 18

    Jun

  • 18

    Jun

  • 20

    Jun

  • 28

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
06/18/18
06/18
12:17
06/18/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
06/18/18
06/18
12:16
06/18/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KHC

Kraft Heinz

$60.94

-0.67 (-1.09%)

12:15
06/18/18
06/18
12:15
06/18/18
12:15
Periodicals
Kraft Heinz mulls sale of children's drink brand in India, Bloomberg says »

Kraft Heinz is weighing a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
06/18/18
06/18
12:15
06/18/18
12:15
General news
Euro$ interest rate futures continue to claw back »

Euro$ interest rate…

ATVI

Activision Blizzard

$77.65

0.21 (0.27%)

, EA

Electronic Arts

$144.71

-1.92 (-1.31%)

12:13
06/18/18
06/18
12:13
06/18/18
12:13
Hot Stocks
WHO adds 'Gaming Disorder' to ICD »

The World Health…

ATVI

Activision Blizzard

$77.65

0.21 (0.27%)

EA

Electronic Arts

$144.71

-1.92 (-1.31%)

GME

GameStop

$14.27

0.355 (2.55%)

TTWO

Take-Two

$119.78

-1.74 (-1.43%)

MSFT

Microsoft

$100.58

0.34 (0.34%)

NTDOY

Nintendo

$0.00

(0.00%)

ZNGA

Zynga

$4.28

-0.045 (-1.04%)

SNE

Sony

$48.12

-0.99 (-2.02%)

UBSFY

Ubisoft

$0.00

(0.00%)

TCEHY

Tencent

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 19

    Jun

  • 19

    Jun

  • 28

    Jun

BBBY

Bed Bath & Beyond

$20.17

-0.01 (-0.05%)

12:10
06/18/18
06/18
12:10
06/18/18
12:10
Options
Earnings hedge in Bed, Bath and Beyond »

Earnings hedge in Bed,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$52.74

-0.87 (-1.62%)

12:09
06/18/18
06/18
12:09
06/18/18
12:09
Technical Analysis
Technical Take: Momo falls, analyst action »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.